Transplant Genomics, Inc. Founders Awarded US Patent Covering Detection of “Silent” Sub-Clinical Rejection in Stable Kidney Transplant RecipientsTruGraf2020-02-25T18:07:26-06:00October 2019|Read More
Transplant Genomics, Inc. Confirms TruGraf® Will Receive Medicare Coverage Effective November 25, 2019TruGraf2020-02-25T18:07:26-06:00October 2019|Read More
Medicare Issues Draft Local Coverage Determination (LCD) for Transplant Genomics’ TruGraf® Blood Test as Alternative to Surveillance BiopsiesTruGraf2020-02-25T18:07:27-06:00March 2019|Read More
Studies Presented at American Transplant Congress Support Clinical Utility of TGI’s TruGraf® Tests for Management of Kidney Transplant RecipientsTruGraf2020-02-25T18:07:27-06:00June 2018|Read More
Clinical Utility Study Indicates Potential for TruGraf™ Test to Replace Surveillance Biopsies in Kidney Transplant Recipients with Stable Renal FunctionTruGraf2020-02-25T18:07:28-06:00November 2017|Read More
Study Shows TruGraf Blood Test Enables Non-invasive Detection of Immune Quiescent Kidney Transplant RecipientsTruGraf2020-02-25T18:07:28-06:00October 2017|Read More
U.S. patent issues for gene expression profiles associated with chronic kidney allograft rejection, licensed exclusively to Transplant Genomics Inc.TruGraf2020-02-25T18:07:28-06:00September 2017|Read More
Genomic Signature for Predicting Acute Rejection in Liver Transplant Patients to be Presented at the American Transplant CongressTruGraf2020-02-25T18:07:29-06:00May 2017|Read More
Transplant Genomics enters collaboration with Mayo ClinicTruGraf2020-02-25T18:07:29-06:00June 2016|Read More
Transplant Genomics Announces Immunosuppressive Clinical Trials Collaboration with Astellas PharmaceuticalsTruGraf2020-02-25T18:07:30-06:00May 2016|Read More
